| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $1.25B | +8.7% |
| Cost of Revenue | $382.6M | +0.1% |
| Gross Profit | $870.9M | +12.9% |
| R&D Expense | $182.5M | -5.8% |
| SG&A Expense | $526.3M | +1.6% |
| Operating Income | $129.1M | +288.4% |
| Pre-tax Income | $88.3M | +208.7% |
| Income Tax | $25.1M | +125.3% |
| Net Income | $63.2M |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $428.9M | +60.9% |
| Accounts Receivable | $193.2M | -10.2% |
| Inventory | $147.6M | -0.2% |
| Current Assets | $1.13B | +14.1% |
| Total Assets | $2.51B | +3.2% |
| Current Liabilities | $392.1M | +17.1% |
| Long-term Debt | $627.0M | +7.0% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $183.0M | +144.3% |
| Capital Expenditures | $47.1M | +34.7% |
| Investing Cash Flow | -$48.2M | -19.4% |
| Financing Cash Flow | $18.6M | -13.7% |
| Free Cash Flow | $135.9M | +240.4% |
| +260.4% |
| EPS (Basic) | $1.17 | +254.5% |
| EPS (Diluted) | $1.16 | +262.5% |
| Total Liabilities |
| $1.19B |
| +3.0% |
| Stockholders' Equity | $1.32B | +3.3% |